Focused On-demand Library for Solute carrier organic anion transporter family member 2A1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q92959

UPID:
SO2A1_HUMAN

ALTERNATIVE NAMES:
OATP2A1; PHOAR2; Prostaglandin transporter; Solute carrier family 21 member 2

ALTERNATIVE UPACC:
Q92959; Q86V98; Q8IUN2

BACKGROUND:
The protein Solute carrier organic anion transporter family member 2A1, known alternatively as OATP2A1 or Prostaglandin transporter, is integral in prostaglandin and thromboxane transport. These substances are vital for numerous bodily functions, from regulating blood pressure to modulating inflammation. SLCO2A1's role in prostaglandin clearance from the bloodstream is particularly critical for the termination of prostaglandin signaling, ensuring physiological balance.

THERAPEUTIC SIGNIFICANCE:
SLCO2A1's involvement in diseases such as Hypertrophic osteoarthropathy underscores its therapeutic potential. By targeting SLCO2A1, novel treatments for these debilitating bone and skin conditions could be developed, offering hope for patients suffering from these rare disorders. The exploration of SLCO2A1's function and its genetic variants paves the way for innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1081 of 8789